Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme.
Christophe HézodePascal LebrayVictor De LedinghenFabien ZoulimVincent Di MartinoNathalie BoyerDominique LarreyDanielle Botta-FridlundChristine SilvainHélène FontaineLouis D'AlterocheVincent LeroyMarc BourliereIsabelle Hubert-FouchardDominique GuyaderIsabelle RosaEric Nguyen-KhacLarysa FedchukRaoudha AkremiYacia BennaiAnne FilipovicsYue ZhaoJean-Pierre BronowickiPublished in: Liver international : official journal of the International Association for the Study of the Liver (2017)
Daclatasvir+sofosbuvir achieved high SVR12 rates and was well tolerated in this large real-world cohort of GT3-infected patients with advanced liver disease, without benefit of ribavirin in those treated 24 weeks.